Supriya Lifescience Partners with KIIT to Develop Affordable Wound Healing Gel

The GelHeal project focuses on creating a gel-based cream that offers a simple and cost-effective solution for wound healing, specifically targeting deep wounds and scar-free skin regeneration.

Mumbai-based pharmaceutical company Supriya Lifescience specialising in active pharmaceutical ingredients (API) and contract development and manufacturing (CDMO), has entered into a strategic partnership with the Kalinga Institute of Industrial Technology (KIIT). 

The partnership aims to advance wound care by developing GelHeal, a protein-based crosslinked hydrogel.

Commenting on the same, Dr Satish Wagh, founder and chairman of Supriya Lifescience, said, "Supriya Lifescience is committed to diversifying our business by leveraging our world-class CDMO capabilities to offer niche healthcare products. We believe that innovations like GelHeal, the simplest and most affordable wound healing gel, will establish Supriya Lifescience as an integrated healthcare provider.”

The GelHeal project focuses on creating a gel-based cream that offers a simple and cost-effective solution for wound healing, specifically targeting deep wounds and scar-free skin regeneration. 

The innovation can potentially address a wide range of medical issues, from third-degree wounds, cuts, and bite or ballistic wounds to diabetic foot ulcers, pressure ulcers, venous leg ulcers, and surgical wounds.

The unique aspect of GelHeal lies in its ability to provide in-situ scaffolding for mechanical support within deep wounds, resulting in effective skin regeneration without leaving unsightly scars. This approach marks a significant advancement in the field of dermatology and skin grafting.

Supriya Lifescience, established in 1987, is well-known for its contributions to the API manufacturing industry. The company specialises in various therapeutic segments, including Anti-Histamine, Anti-Allergics, Vitamins, Anaesthetics, and Anti-Asthmatics. 

It is recognised for its strong research and development capabilities and worldwide compliant facilities.

This collaboration follows Supriya Lifescience's recent agreement with KIIT to develop Quickblue, an oral cancer detection kit. This novel kit aims to transform oral cancer diagnosis, offering a faster and more affordable alternative to traditional biopsy methods.